| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2018 | AVIDBIOTICS CORP. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 003 | 3 | NIH | 12/5/2022 | -$30,409 |
| | 2023 | 2018 | AVIDBIOTICS CORP. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 000 | 3 | NIH | 11/29/2022 | -$30,409 |
| | 2023 | 2018 | AVIDBIOTICS CORP. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 002 | 3 | NIH | 12/2/2022 | $60,818 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2017 | AVIDBIOTICS CORP. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R21AI121692 | Development of Modified R-type Bacteriocins to Specifically Target C. difficile and Prevent Relapse of CDIs | 000 | 2 | NIH | 8/17/2022 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2018 | AVIDBIOTICS CORP. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 000 | 3 | NIH | 6/17/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $524,255 ) |
| | 2018 | 2018 | AVIDBIOTICS CORP. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 001 | 3 | NIH | 4/17/2018 | $524,255 |
| | 2018 | 2018 | AVIDBIOTICS CORP. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 001 | 3 | NIH | 4/17/2018 | -$524,255 |
| | 2018 | 2018 | AVIDBIOTICS CORP. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 000 | 3 | NIH | 11/24/2017 | $524,255 |
|
| Issue Date FY: 2017 ( Subtotal = $101,591 ) |
| | 2017 | 2017 | AVIDBIOTICS CORP. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R21AI121692 | Development of Modified R-type Bacteriocins to Specifically Target C. difficile and Prevent Relapse of CDIs | 001 | 2 | NIH | 12/6/2016 | $119,517 |
| | 2017 | 2016 | AVIDBIOTICS CORP. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R21AI121692 | Development of Modified R-type Bacteriocins to Specifically Target C. difficile and Prevent Relapse of CDIs | 000 | 1 | NIH | 11/29/2016 | -$17,926 |
|
| Issue Date FY: 2016 ( Subtotal = $342,006 ) |
| | 2016 | 2016 | AVIDBIOTICS CORPORATION | 300 UTAH AVENUE | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | R21AI121692 | Development of Modified R-type Bacteriocins to Specifically Target C. difficile and Prevent Relapse of CDIs | 001 | 1 | NIH | 8/19/2016 | $342,006 |
| | 2016 | 2016 | AVIDBIOTICS CORPORATION | 300 UTAH AVENUE | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | R21AI121692 | Development of Modified R-type Bacteriocins to Specifically Target C. difficile and Prevent Relapse of CDIs | 001 | 1 | NIH | 8/19/2016 | -$342,006 |
| | 2016 | 2016 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R21AI121692 | Development of Modified R-type Bacteriocins to Specifically Target C. difficile and Prevent Relapse of CDIs | 000 | 1 | NIH | 11/25/2015 | $342,006 |
|
| Issue Date FY: 2013 ( Subtotal = $616,078 ) |
| | 2013 | 2013 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R43AI098186 | TARGETABLE BACTERICIDAL PROTEINS TO SPECIFICALLY KILL CLOSTRIDIUM DIFFICILE BACTE | 000 | 2 | NIH | 8/1/2013 | $300,000 |
| | 2013 | 2013 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R43TR001011 | DIVERSIFYING MICA TO CREATE TARGETED ADAPTERS TO RECRUIT AND ACTIVATE NK CELLS TO | 000 | 1 | NIH | 9/10/2013 | $316,078 |
| | 2013 | 2011 | AVIDBIOTICS CORPORATION | 300 UTAH AVENUE | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | R43AI088863 | CREATE, EVALUATE AND DEVELOP PRE-CLINICALLY AN ENGINEERED R-TYPE PYOCIN TO SPECIF | 000 | 2 | NIH | 5/8/2013 | $0 |
| | 2013 | 2011 | AVIDBIOTICS CORPORATION | 300 UTAH AVENUE | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | R43AI088979 | TARGETED SOLUBLE MICA MOLECULES TO RECRUIT INNATE IMMUNITY CELLS TO KILL SPECIFIC | 000 | 2 | NIH | 1/29/2013 | $0 |
|
| Issue Date FY: 2012 ( Subtotal = $300,000 ) |
| | 2012 | 2012 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R43AI098186 | TARGETABLE BACTERICIDAL PROTEINS TO SPECIFICALLY KILL CLOSTRIDIUM DIFFICILE BACTE | 000 | 1 | NIH | 9/24/2012 | $300,000 |
| | 2012 | 2011 | AVIDBIOTICS CORPORATION | 300 UTAH AVENUE | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | R43AI088979 | TARGETED SOLUBLE MICA MOLECULES TO RECRUIT INNATE IMMUNITY CELLS TO KILL SPECIFIC | 000 | 2 | NIH | 5/1/2012 | $0 |
|
| Issue Date FY: 2011 ( Subtotal = $1,009,838 ) |
| | 2011 | 2011 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R43AI088979 | TARGETED SOLUBLE MICA MOLECULES TO RECRUIT INNATE IMMUNITY CELLS TO KILL SPECIFIC | 000 | 2 | NIH | 3/11/2011 | $300,000 |
| | 2011 | 2011 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R43AI088863 | CREATE, EVALUATE AND DEVELOP PRE-CLINICALLY AN ENGINEERED R-TYPE PYOCIN TO SPECIF | 000 | 2 | NIH | 4/21/2011 | $228,071 |
| | 2011 | 2011 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R43AI084295 | ENGINEERED R-TYPE PYOCINS AS BACTERICIDAL AGENTS AGAINST E.COLI O157:H7 | 000 | 2 | NIH | 8/8/2011 | $308,517 |
| | 2011 | 2011 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R21AI085318 | GENERATING A LIBRARY OF ANTIMICROBIAL R-TYPE PYOCINS AGAINST ENTERIC BACTERIA | 000 | 2 | NIH | 8/9/2011 | $173,250 |
|
| Issue Date FY: 2010 ( Subtotal = $1,572,383 ) |
| | 2010 | 2010 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R43AI084295 | ENGINEERED R-TYPE PYOCINS AS BACTERICIDAL AGENTS AGAINST E.COLI O157:H7 | 000 | 2 | NIH | 7/21/2010 | $317,576 |
| | 2010 | 2010 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R43AI088863 | CREATE, EVALUATE AND DEVELOP PRE-CLINICALLY AN ENGINEERED R-TYPE PYOCIN TO SPECIF | 000 | 1 | NIH | 5/10/2010 | $284,032 |
| | 2010 | 2010 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R21AI085318 | GENERATING A LIBRARY OF ANTIMICROBIAL R-TYPE PYOCINS AGAINST ENTERIC BACTERIA | 000 | 1 | NIH | 9/23/2010 | $200,000 |
| | 2010 | 2010 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R43AI088979 | TARGETED SOLUBLE MICA MOLECULES TO RECRUIT INNATE IMMUNITY CELLS TO KILL SPECIFIC | 000 | 1 | NIH | 3/15/2010 | $300,000 |
| | 2010 | 2010 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R44AI066449 | NON-CLINICAL DEVELOPMENT OF BACTERICIDAL PROTEINS TARGETING PLAGUE | 001 | 3 | NIH | 8/16/2010 | $470,775 |
| | 2010 | 2009 | AVIDBIOTICS CORPORATION | 300 UTAH AVENUE | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | R44AI066449 | NON-CLINICAL DEVELOPMENT OF BACTERICIDAL PROTEINS TARGETING PLAGUE | 000 | 2 | NIH | 11/27/2009 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $920,221 ) |
| | 2009 | 2009 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R44AI066449 | NON-CLINICAL DEVELOPMENT OF BACTERICIDAL PROTEINS TARGETING PLAGUE | 000 | 2 | NIH | 9/11/2009 | $602,645 |
| | 2009 | 2009 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080-4811 | SAN MATEO | USA | R43AI084295 | ENGINEERED R-TYPE PYOCINS AS BACTERICIDAL AGENTS AGAINST E.COLI O157:H7 | 000 | 1 | NIH | 7/29/2009 | $317,576 |
|
| Issue Date FY: 2006 ( Subtotal = $494,982 ) |
| | 2006 | 2006 | AVIDBIOTICS CORPORATION | 230 EAST GRAND AVENUE | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | R43AI066449 | HOST RANGE DIVERSITY OF BACTERIOPHAGE FOR Y. PESTIS | 000 | 1 | NIH | 4/28/2006 | $494,982 |
|
|
